Publication | Open Access

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Epithelial-mesenchymal TransitionBreast OncologyOncologyMesenchymal–epithelial TransitionMedicineBreast Cancer CellsEpithelial–mesenchymal TransitionCancer Cell BiologyEpithelial-mesenchymal InteractionsBreast CancerCell BiologyCancer BiologyRadiation OncologyCancer ResearchTumor BiologyCancer Growth